Biophan to Spotlight Nanotechnology and Other Solutions at Rodman & Renshaw Techvest Healthcare Investor Conference
|CEO Michael Weiner to Detail Progress in Monetizing IP Portfolio through Technology Licensing Agreements|
“We will discuss our plans to further commercialize our broad IP portfolio and other promising initiatives for high revenue growth opportunities”
Biophan Technologies, Inc. (OTCBB: BIPH; FWB: BTN), a developer of next-generation medical technology, has announced that CEO Michael Weiner will present a sampling of the Company's major business and scientific achievements at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference, a high-profile conference for institutional investors and other professionals active in the global biotechnology industry, scheduled for November 7-9 in the New York Palace Hotel in New York City.
Mr. Weiner will present Biophan's nanotechnology-based and other cutting-edge innovations for the medical device industry. He will also discuss revenue implications of the Company's proprietary technologies and solutions.
Among key breakthrough innovations Mr. Weiner will review are solutions that enable vascular stents, vena cava filters and other devices to be accurately imaged with Magnetic Resonance Imaging (MRI) systems. Biophan has developed nanotechnology-based and other proprietary solutions to create "visible stents" that can be imaged with MRI to provide physicians with the ability to easily and safely assess health conditions inside implanted stents, including in-stent restenosis, or to use MRI to image vena cava filters to screen for the presence of blood clots.
Mr. Weiner's presentation is scheduled for Tuesday, November 8, at 12:20 p.m., in the Adams room. Topics Mr. Weiner plans to discuss include the Company's recent progress in development of its intellectual property portfolio, its licensing and equity agreement with medical device manufacturer Boston Scientific (NYSE: BSX), and the Company's recent initiative to enter the estimated $28 billion cardiovascular device marketplace.
Mr. Weiner will outline the Company's various initiatives to ensure the successful monetization of its extensive intellectual property portfolio of more than 156 US patents, licenses and applications, as well as international applications.
"We will discuss our plans to further commercialize our broad IP portfolio and other promising initiatives for high revenue growth opportunities," Mr. Weiner said. "It's extremely valuable for us to reach investment professionals active in the biomedical space, to provide additional exposure regarding our progress in developing biomedical technology innovations to improve healthcare delivery."
Biophan is developing a range of new technologies and solutions to address needs in many multibillion-dollar segments of the global biomedical industry. Among its technologies are solutions to enable medical devices to be safely and/or accurately imaged by Magnetic Resonance Imaging (MRI) systems. Such devices include pacemakers, defibrillators and neurostimulators, which currently are contraindicated for use by MRI - leaving many patients without access to a crucial diagnostic imaging option if and when they need it.
"We anticipate a shift in medical device designs that currently keep MRI out of reach for many patients, and we are proudly at the forefront of that movement," Mr. Weiner added. "Over $12 billion worth of devices are sold every year with shortcomings that make MRI inaccessible for imaging or safety reasons. We believe that these problems must be and can be solved, and we have started to see leading manufacturers such as Boston Scientific taking steps in that direction."
About Rodman & Renshaw
Since 1951, Rodman & Renshaw has been dedicated to serving the needs of companies in emerging growth sectors and the investors that seek value in these companies. Although the sectors and their companies have changed over the last five decades, the hallmarks of emerging growth companies remain constant - entrepreneurial spirit, market-defining innovations and cutting-edge expertise. We seek to identify and service undervalued emerging growth companies that are positioned to significantly outperform both their peers and the market in general. Throughout the years, experience has demonstrated that certain positive traits are reliable indicators of a company's potential - entrepreneurial spirit and drive of its executives and employees; vision to recognize and pursue opportunities where others see only obstacles and risks; ability to develop and bring to market innovative products, services and technologies addressing important unmet needs; skill and perseverance to succeed over the long-haul. For more information, please visit http://www.rodmanandrenshaw.com.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops technologies that enable implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and devices such as stents to be safely and effectively imaged under MRI. Biophan is developing these same technologies to provide new MRI contrast agents. Other applications include drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 156 U.S. patents, licenses, or applications. This total includes 42 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 106 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat and optical catheter technologies. Biophan has joint development and licensing agreements with Boston Scientific and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. Biophan is also listed on the Frankfurt Stock Exchange under the ticker symbol "BTN." For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.